Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity.

Teng YK, Wheater G, Hogan VE, Stocks P, Levarht EW, Huizinga TW, Toes RE, van Laar JM.

Arthritis Res Ther. 2012 Mar 12;14(2):R57. doi: 10.1186/ar3770.

PMID:
22409963
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.

Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM.

Arthritis Rheum. 2007 Dec;56(12):3909-18.

PMID:
18050222
[PubMed - indexed for MEDLINE]
Free Article
3.

Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.

Váncsa A, Szabó Z, Szamosi S, Bodnár N, Végh E, Gergely L, Szucs G, Szántó S, Szekanecz Z.

J Rheumatol. 2013 May;40(5):565-71. doi: 10.3899/jrheum.111488. Epub 2013 Apr 1.

PMID:
23547216
[PubMed - indexed for MEDLINE]
4.

Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium.

Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B, Spencer J, Pitzalis C.

PLoS Med. 2009 Jan 13;6(1):e1. doi: 10.1371/journal.pmed.0060001.

PMID:
19143467
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

B-cells and their targeting in rheumatoid arthritis--current concepts and future perspectives.

Nakken B, Munthe LA, Konttinen YT, Sandberg AK, Szekanecz Z, Alex P, Szodoray P.

Autoimmun Rev. 2011 Nov;11(1):28-34. doi: 10.1016/j.autrev.2011.06.010. Epub 2011 Jul 14. Review.

PMID:
21777703
[PubMed - indexed for MEDLINE]
6.

B cell therapies for rheumatoid arthritis: beyond B cell depletion.

Calero I, Nieto JA, Sanz I.

Rheum Dis Clin North Am. 2010 May;36(2):325-43. doi: 10.1016/j.rdc.2010.02.003. Review.

PMID:
20510237
[PubMed - indexed for MEDLINE]
7.

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.

Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC.

Arthritis Rheum. 2006 Mar;54(3):723-32.

PMID:
16508933
[PubMed - indexed for MEDLINE]
Free Article
8.

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.

Arthritis Rheum. 2007 May;56(5):1417-23.

PMID:
17469098
[PubMed - indexed for MEDLINE]
Free Article
9.

Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.

Popa C, Leandro MJ, Cambridge G, Edwards JC.

Rheumatology (Oxford). 2007 Apr;46(4):626-30. Epub 2006 Dec 19.

PMID:
17189244
[PubMed - indexed for MEDLINE]
Free Article
10.

CD19: a promising B cell target for rheumatoid arthritis.

Tedder TF.

Nat Rev Rheumatol. 2009 Oct;5(10):572-7. doi: 10.1038/nrrheum.2009.184. Review.

PMID:
19798033
[PubMed - indexed for MEDLINE]
11.

Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses.

Anderson AE, Lorenzi AR, Pratt A, Wooldridge T, Diboll J, Hilkens CM, Isaacs JD.

Rheumatology (Oxford). 2012 Aug;51(8):1397-406. doi: 10.1093/rheumatology/kes038. Epub 2012 Mar 24.

PMID:
22447884
[PubMed - indexed for MEDLINE]
Free Article
12.

Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis.

Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, Gremese E, Ravagnani V, Benucci M, Podestà E, Atzeni F, Mannocci A, Biasi D, Manfredi M, Sarzi-Puttini P, Laganà B, Montecucco C.

PLoS One. 2012;7(7):e40362. doi: 10.1371/journal.pone.0040362. Epub 2012 Jul 30.

PMID:
22859946
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.

Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD.

Arthritis Rheum. 2003 Aug;48(8):2146-54.

PMID:
12905467
[PubMed - indexed for MEDLINE]
Free Article
14.

Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy.

Walsh CA, Fearon U, FitzGerald O, Veale DJ, Bresnihan B.

Clin Exp Rheumatol. 2008 Jul-Aug;26(4):656-8.

PMID:
18799100
[PubMed - indexed for MEDLINE]
15.

Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study.

Teng YK, Verburg RJ, Verpoort KN, Diepenhorst GM, Bajema IM, van Tol MJ, Jol-van der Zijde EC, Toes RE, Huizinga TW, van Laar JM.

Arthritis Res Ther. 2007;9(5):R106.

PMID:
17927821
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Improvement of refractory rheumatoid arthritis after depletion of B cells.

Kneitz C, Wilhelm M, Tony HP.

Scand J Rheumatol. 2004;33(2):82-6.

PMID:
15163108
[PubMed - indexed for MEDLINE]
17.

Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.

Dass S, Vital EM, Emery P.

Expert Opin Pharmacother. 2006 Dec;7(18):2559-70. Review.

PMID:
17150009
[PubMed - indexed for MEDLINE]
18.

Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.

Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M.

Arthritis Res Ther. 2009;11(4):R123. doi: 10.1186/ar2789. Epub 2009 Aug 17.

PMID:
19686595
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

B cells in rheumatoid arthritis.

Bugatti S, Codullo V, Caporali R, Montecucco C.

Autoimmun Rev. 2007 Dec;7(2):137-42. Epub 2007 Mar 26. Review.

PMID:
18035324
[PubMed - indexed for MEDLINE]
20.

Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.

Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM.

Ann Rheum Dis. 2009 Jun;68(6):1011-6. doi: 10.1136/ard.2008.092791. Epub 2008 Jul 22.

PMID:
18647852
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk